Die Information für Ärzte und Apotheker
Neutral, unabhängig und anzeigenfrei
arznei-telegramm®
previous issue next issue
This is a translation of the table of contents. One article is translated and freely available.

SPOT ON
Medical conditions of unclear origin: can these be triggered by a medication?

NEW ON THE MARKET
Lebrikizumab (EBGLYSS) for the treatment of atopic dermatitis
Hexamidine eye drops (ZAMIDINE) against conjunctivitis and blepharitis?

THERAPY FROM A CRITICAL VIEWPOINT
Smoking cessation: varenicline and nicotine replacement with added benefit

IN BRIEF
Flu vaccines: WHO recommends trivalent vaccines
Thromboembolic risk of chlormadinone-containing contraceptives (e.g. BELARA) and of the long cycle contraceptive SEASONIC is in the midfield range
Delivery failure of sodium perchlorate (IRENAT) results in additional costs of several million euros
Overall survival shortened – approval of melphalan flufenamide (PEPAXTI) revoked in the USA, but not in the EU

SIDE EFFECTS
Respiratory syncytial virus vaccines ABRYSVO and AREXVY: possible risk of Guillain-Barré syndrome?  free article 
Isotretinoine: prescriptions for young women are increasing
News on the safety of testosterone (e.g. TESTOGEL)
© 2024 arznei-telegramm